All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-10-04T16:18:04.000Z

After the latest follow up of the MASTER trial, can we safely implement MRD-guided frontline treatment in the clinic?

By Erika Roa, Mark Maitland, Addy Dullaghan
Featured
Luciano Costa
Oct 4, 2021
Share:

Bookmark this article

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: After the latest follow-up of the MASTER trial, can we safely implement minimal residual disease (MRD)-guided frontline treatment in the clinic?

MASTER trial: Can we safely implement MRD-guided frontline treatment in the clinic?

Costa discusses the recent results of the single-arm, phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

 

More about...
CarfilzomibDaratumumabIMWIMW 2021LenalidomideMASTERNewly diagnosed multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
19 votes - 12 days left ...

Related articles

Add bookmark

The role of consolidation after autologous stem cell transplantation

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria Mateos, Nina Shah,...

Jul 20, 2022
Add bookmark

The role of consolidation after autologous stem cell transplantation

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that...

Jul 20, 2022
Add bookmark

Continuous versus fixed duration therapy in multiple myeloma: The great debate

Considerable advances have been made in the treatment of multiple myeloma (MM) over the past 2 decades, including alternatives to alkylator-based induction regimens and...

Nov 26, 2021
Add bookmark

Continuous versus fixed duration therapy in multiple myeloma: The great debate

Considerable advances have been made in the treatment of multiple myeloma (MM) over the past 2 decades, including...

Nov 26, 2021

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox